In the Phase 1 trial, a single intravenous dose of NTLA-2001 effectively knocked out the mutant TTR gene, reducing circulating TTR protein levels by up to 87% in patients with hereditary TTR amyloidosis with polyneuropathy. Here, TTR is linked to familial amyloid neuropathy.